Results 21 to 30 of about 15,580 (201)
Journal of Virus Eradication, 2015 Background: In 2013, an estimated 686,000 people died from hepatitis B virus (HBV) infection worldwide. Mass treatment programmes for hepatitis B will require very low drug costs.
Andrew Hill +6 more
doaj +1 more source
Frontiers in Oncology, 2023 ObjectiveIn this study, we aimed to perform a network meta-analysis to compare the effectiveness of NAs in decreasing the reactivation of HBV, reducing chemotherapy disruption, and improving survival in oncology patients.MethodsRelevant randomized ...
Yuqing Zhao +12 more
doaj +1 more source
A cost utility and cost effectiveness analysis of different oral antiviral medications in patients with HBeAg-Negative chronic hepatitis B in Iran: an economic microsimulation decision model [PDF]
, 2016 Background: Although hepatitis B infection is the major cause of chronic liver disease in Iran, no studies have employed economic evaluations of the medications used to treat Iranian patients with chronic hepatitis B (CHB).
Alavian, Seyed Moayed +9 more
core +1 more source
Gastroenterology Research and Practice, 2016 Background. Currently, both of entecavir and lamivudine are effective for patients with HBV-associated acute-on-chronic liver failure (ACLF). However, there is no consensus on the efficacy of entecavir versus lamivudine for patients with HBV-associated ...
Jiao Yang, Hang Sun, Qi Liu
doaj +1 more source
The Saudi Journal of Gastroenterology, 2015 Background/Aim: Hepatic steatosis may influence the response to antivirals in chronic hepatitis B patients. This study aimed to compare the efficacy of entecavir and tenofovir in nucleos(t) ide-naive chronic hepatitis B patients with hepatosteatosis ...
Zeynal Dogan +3 more
doaj +1 more source
A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. [PDF]
PLoS ONE, 2013 BACKGROUND: Prescribers, payors and healthcare decision-makers are increasingly examining the value of treatments. This study aims at analyzing economic value of chronic hepatitis B (CHB) treatment options, which are available in Korea.
Jun Yong Park +8 more
doaj +1 more source
Liver transplantation for viral hepatitis in 2015 [PDF]
, 2016 Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and for patients with liver cell cancer related to liver disease.
Bortoluzzi, Ilaria +8 more
core +1 more source
[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]
Clinical Management Issues, 2015 BACKGROUND AND AIM: The current treatment of chronic hepatitis B infection (CHBV) has achieved several step-ups thanks to the introduction of the new-generation nucleos(t)ide analogs.
Fabio Tarsetti +4 more
doaj +1 more source
Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression? [PDF]
, 2006 The availability of nucleoside analogues has broadened treatment options for chronic hepatitis B virus (HBV ) infection. Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir,
Buster, E.H.C.J. (Erik) +1 more
core +9 more sources
Beni-Suef University Journal of Basic and Applied Sciences, 2022 Background A meta-analysis was made to assess the impact of entecavir comparison with tenofovir disoproxil fumarate as nucleos(t)ide analogue on hepatic cellular carcinoma (HCC). The study had subjects with chronic hepatitis B virus (HBV).
Sara M. Tony +3 more
doaj +1 more source